JP2016527252A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016527252A5 JP2016527252A5 JP2016529843A JP2016529843A JP2016527252A5 JP 2016527252 A5 JP2016527252 A5 JP 2016527252A5 JP 2016529843 A JP2016529843 A JP 2016529843A JP 2016529843 A JP2016529843 A JP 2016529843A JP 2016527252 A5 JP2016527252 A5 JP 2016527252A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- carrier molecule
- receptor substrate
- composition according
- dextran backbone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 60
- 239000000203 mixture Substances 0.000 claims description 53
- 210000004027 cell Anatomy 0.000 claims description 45
- 239000000758 substrate Substances 0.000 claims description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- 208000035475 disorder Diseases 0.000 claims description 30
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 claims description 20
- 210000001124 body fluid Anatomy 0.000 claims description 16
- CERZMXAJYMMUDR-QBTAGHCHSA-N 5-amino-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosonic acid Chemical compound N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO CERZMXAJYMMUDR-QBTAGHCHSA-N 0.000 claims description 10
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 10
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 10
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 10
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 10
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims description 10
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 10
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 10
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 10
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 10
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 10
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 10
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 claims description 10
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 10
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 8
- 150000004676 glycans Chemical class 0.000 claims description 8
- 229920001282 polysaccharide Polymers 0.000 claims description 8
- 239000005017 polysaccharide Substances 0.000 claims description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 238000009007 Diagnostic Kit Methods 0.000 claims description 6
- 229920000057 Mannan Polymers 0.000 claims description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 201000008827 tuberculosis Diseases 0.000 claims description 6
- 239000010839 body fluid Substances 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 230000033115 angiogenesis Effects 0.000 claims description 3
- 210000005005 sentinel lymph node Anatomy 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 210000001179 synovial fluid Anatomy 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 229950010544 tilmanocept Drugs 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361857232P | 2013-07-22 | 2013-07-22 | |
| US61/857,232 | 2013-07-22 | ||
| US201361879649P | 2013-09-18 | 2013-09-18 | |
| US61/879,649 | 2013-09-18 | ||
| PCT/US2014/047708 WO2015013341A1 (en) | 2013-07-22 | 2014-07-22 | Compositions, methods and kits for diagnosing and treating cd206 expressing cell-related disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016527252A JP2016527252A (ja) | 2016-09-08 |
| JP2016527252A5 true JP2016527252A5 (enExample) | 2017-08-31 |
| JP6607854B2 JP6607854B2 (ja) | 2019-11-20 |
Family
ID=51352773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016529843A Active JP6607854B2 (ja) | 2013-07-22 | 2014-07-22 | Ｃｄ２０６発現細胞関連障害を診断および処置するための組成物、方法およびキット |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20150023876A1 (enExample) |
| EP (1) | EP3024493A1 (enExample) |
| JP (1) | JP6607854B2 (enExample) |
| KR (2) | KR20210095972A (enExample) |
| CN (2) | CN105764529A (enExample) |
| AU (3) | AU2014293198A1 (enExample) |
| CA (1) | CA2918782C (enExample) |
| HK (1) | HK1225623A1 (enExample) |
| IL (1) | IL243645B (enExample) |
| WO (1) | WO2015013341A1 (enExample) |
| ZA (1) | ZA201600453B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100196272A1 (en) | 2009-01-30 | 2010-08-05 | Neoprobe Corporation | Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran |
| US10806803B2 (en) | 2014-07-17 | 2020-10-20 | Ohio State Innovation Foundation | Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis |
| JP6722663B2 (ja) * | 2014-07-17 | 2020-07-15 | オハイオ ステート イノベーション ファウンデーション | マクロファージおよび他のマンノース結合ｃ型レクチン受容体高発現細胞を標的化するための化合物および組成物、ならびにそれらを使用して治療するおよび診断する方法 |
| JP2018528235A (ja) * | 2015-09-25 | 2018-09-27 | セリーン・エルエルシー | Ｓｎ−１１７ｍ標識マンノース結合デキストランアミン |
| MX2019003897A (es) * | 2016-10-04 | 2019-11-18 | Cardinal Health 414 Llc | Composiciones y metodos para el diagnostico y el tratamiento de trastornos relacionados con macrofagos que utilizan el transportador macromolecular a base de carbohidratos. |
| MX2019004033A (es) * | 2016-10-07 | 2019-12-05 | Navidea Biopharmaceuticals Inc | Compuestos y composiciones para el tratamiento de la leishmaniasis y metodos de diagnostico y tratamiento que utilizan los mismos. |
| US11007272B1 (en) | 2016-10-07 | 2021-05-18 | Navidea Biopharmaceuticals, Inc. | Compounds and methods for diagnosis and treatment of viral infections |
| US11363709B2 (en) | 2017-02-24 | 2022-06-14 | BWXT Isotope Technology Group, Inc. | Irradiation targets for the production of radioisotopes |
| US11286172B2 (en) | 2017-02-24 | 2022-03-29 | BWXT Isotope Technology Group, Inc. | Metal-molybdate and method for making the same |
| JP2020521021A (ja) * | 2017-05-19 | 2020-07-16 | ナビディア・バイオファーマシューティカルズ，インコーポレーテッド | Ｃｄ２０６＋マクロファージ特異的分子画像化のプローブ組成物および方法、ならびにヒトにおける動脈壁マクロファージ浸潤の非侵襲的定量化 |
| EP3655107A4 (en) * | 2017-07-21 | 2021-04-28 | Navidea Biopharmaceuticals, Inc. | Use of 99mtc-tilmanocept and related molecular constructs for identifying and diagnosing malignant tumors and for monitoring therapeutic anti-tumor interventions |
| CN114025666A (zh) * | 2019-01-25 | 2022-02-08 | 纳维迪亚生物制药有限公司 | 用于评估巨噬细胞介导的病理学的组合物和方法 |
| GB201902810D0 (en) * | 2019-03-01 | 2019-04-17 | Vidya Holdings Ltd | Disposition of reagents in assay device |
| MX2021011703A (es) * | 2019-03-27 | 2022-01-06 | Navidea Biopharmaceuticals Inc | Composiciones y métodos para alterar el fenotipo de macrófagos. |
| WO2021034953A1 (en) * | 2019-08-19 | 2021-02-25 | Navidea Biopharmaceuticals, Inc. | Compositions and related methods for the ablation of m2 macrophages and myeloid derived suppressor cells |
| CN115151264B (zh) * | 2019-09-30 | 2024-03-12 | 纳维迪亚生物制药有限公司 | 用于阻断甘露糖基化葡聚糖和其它cd206配体脱靶定位的组合物和相关方法 |
| GB201915222D0 (en) * | 2019-10-21 | 2019-12-04 | Univ Court Univ Of Glasgow | Diagnostic and prognostic biomarkers of disease remission in rheumatoid arthritis |
| JP2023533405A (ja) * | 2020-07-08 | 2023-08-03 | ナビディア、バイオファーマスーティカルズ、インコーポレイテッド | 均一に定められた分子量のマンノシル化デキストランおよびその誘導体の合成 |
| WO2022157373A1 (en) * | 2021-01-25 | 2022-07-28 | Vrije Universiteit Brussel | Compositions and kits for in vivo imaging of cardiac sarcoidosis |
| CN113899909A (zh) * | 2021-09-30 | 2022-01-07 | 上海交通大学医学院附属瑞金医院 | 可溶性cd206在制备抗中性粒细胞胞浆抗体相关性血管炎诊断试剂盒中的应用 |
| EP4472643A1 (en) | 2022-02-04 | 2024-12-11 | Navidea Biopharmaceuticals, Inc. | Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking |
| WO2023183922A2 (en) * | 2022-03-25 | 2023-09-28 | Navidea Biopharmaceuticals, Inc. | Competitive self-blocking with unlabeled manocept imaging agents |
| EP4525882A1 (en) | 2022-05-20 | 2025-03-26 | Navidea Biopharmaceuticals, Inc. | Cd206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker |
| US12404349B2 (en) | 2022-10-03 | 2025-09-02 | Navidea Biopharmaceuticals, Inc. | Amide linkages of sugar moieties to amine terminated leashes attached to carbohydrate polymers |
| WO2024178142A1 (en) * | 2023-02-22 | 2024-08-29 | Resolute Science, Inc. | Compositions and methods for targeting tumor-associated macrophages |
| CN119592679B (zh) * | 2024-11-25 | 2025-06-24 | 中日友好医院(中日友好临床医学研究所) | 一种用于评估皮肌炎/抗合成酶综合征相关间质性肺疾病严重程度及预后的新型标记物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE277642T1 (de) * | 1999-05-14 | 2004-10-15 | Univ California | Makromolekular träger auf basis von dextran fur arzneimittel und diagnosticum abgabe |
| JP2004085929A (ja) * | 2002-08-27 | 2004-03-18 | Fuji Photo Optical Co Ltd | 光学素子 |
| US20090311182A1 (en) * | 2004-03-31 | 2009-12-17 | Dong Wang | Macromolecular Delivery Systems for Non-Invasive Imaging, Evaluation and Treatment of Arthritis and Other Inflammatory Diseases |
| US20100196272A1 (en) | 2009-01-30 | 2010-08-05 | Neoprobe Corporation | Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran |
| SG166016A1 (en) * | 2009-04-16 | 2010-11-29 | Fan Wang Yiang | Financial education planner and method of using thereof |
| US9101674B2 (en) * | 2010-03-29 | 2015-08-11 | Vib Vzw | Targeting and in vivo imaging of tumor-associated macrophages |
| US20130330274A1 (en) * | 2012-05-22 | 2013-12-12 | University of Virginia Patent Foundation d/b/a University of Virginia Licensing & Ventures Group | Compositions and methods for detecting and treating cancer |
-
2014
- 2014-07-22 HK HK16113910.2A patent/HK1225623A1/zh unknown
- 2014-07-22 CN CN201480051858.9A patent/CN105764529A/zh active Pending
- 2014-07-22 KR KR1020217023825A patent/KR20210095972A/ko not_active Ceased
- 2014-07-22 WO PCT/US2014/047708 patent/WO2015013341A1/en not_active Ceased
- 2014-07-22 AU AU2014293198A patent/AU2014293198A1/en not_active Abandoned
- 2014-07-22 EP EP14750851.9A patent/EP3024493A1/en active Pending
- 2014-07-22 CA CA2918782A patent/CA2918782C/en active Active
- 2014-07-22 JP JP2016529843A patent/JP6607854B2/ja active Active
- 2014-07-22 CN CN202111299877.1A patent/CN114377143A/zh active Pending
- 2014-07-22 US US14/338,332 patent/US20150023876A1/en not_active Abandoned
- 2014-07-22 KR KR1020167004069A patent/KR102284389B1/ko not_active Expired - Fee Related
-
2016
- 2016-01-17 IL IL243645A patent/IL243645B/en active IP Right Grant
- 2016-01-20 ZA ZA2016/00453A patent/ZA201600453B/en unknown
-
2020
- 2020-01-15 AU AU2020200293A patent/AU2020200293B2/en active Active
-
2021
- 2021-02-19 US US17/180,471 patent/US20220016272A1/en active Pending
-
2022
- 2022-07-13 AU AU2022205225A patent/AU2022205225A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016527252A5 (enExample) | ||
| AU2020200293B2 (en) | Compositions, methods and kits for diagnosing and treating CD206 expressing cell-related disorders | |
| Sattin et al. | Inhibition of DC-SIGN-mediated HIV infection by a linear trimannoside mimic in a tetravalent presentation | |
| WO2023089308A1 (en) | Methods for treating cancer | |
| CA3064277A1 (en) | Cd206+ macrophage-specific molecular imaging probe compositions and methods and the noninvasive quantification of arterial wall macrophage infiltration in humans | |
| AU2011335881B2 (en) | Histone inhibition | |
| CN103768080B (zh) | 一种抗耐药肿瘤的靶向制剂、制备方法及应用 | |
| JP2021502418A (ja) | ポリペプチドを修飾するための組成物及び方法 | |
| Taouai et al. | Unprecedented thiacalixarene fucoclusters as strong inhibitors of ebola cis-cell infection and hcmv-gb glycoprotein/DC-SIGN c-type lectin interaction | |
| IL293026A (en) | Anti-ror-2 antibodies and methods of using them | |
| CA3188677A1 (en) | Imaging and targeting programmed death ligand-1 (pd-li) expression | |
| WO2021036793A1 (en) | Pyroptosis-induced immunotherapy | |
| US20170274087A1 (en) | Saccharide analogs and agents for the diagnosis and therapy of bacterial infections | |
| US20110293515A1 (en) | Heterofunctional segment-poly (ethylene glycol) polymers as delivery vehicles | |
| US20240316036A1 (en) | Disulfide containing therapeutics and diagnostics | |
| Cerney | SYNTHESIS OF OCTAVALENT GLYCODENDRIMERS AS POTENITAL HIV INHIBITORY AGENTS | |
| Wang et al. | Synthesis of polyethylene glycol bis-anti-cancer drug couplings and their anti-tumor activity based on tumor immune dynamic modeling. | |
| WO2021195465A1 (en) | Treatment of acute respiratory distress syndrome and related conditions with antagonists of e-selectin | |
| HK1188125B (en) | Use of polyanions to inhibit the cytotoxic activity of histones in the treatment of sepsis |